• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Sutro shells out lat­est up­date on ovar­i­an can­cer treat­ment, plans for piv­otal tri­al

3 years ago
R&D

BioN­Tech buys out AI part­ner In­staDeep for $440M in bid to be­come ‘tech­nol­o­gy com­pa­ny’

3 years ago
Startups
Deals

Al­to touts new PhI­Ia de­pres­sion da­ta with plans to keep charg­ing for­ward

3 years ago
R&D

What we're see­ing at JPM so far: Up­com­ing BD moves, pipeline up­dates and more

3 years ago
Pharma

Big Phar­mas main­tain pause of Twit­ter ads, spend­ing drops to ze­ro for first week of 2023

3 years ago
Pharma
Marketing

Calithera to shut down af­ter fail­ing to re­vive Take­da as­sets

3 years ago
People

Up­dat­ed: Mod­er­na rounds out 2022 with $18.4B in vac­cine sales, boosts R&D bud­get for 2023

3 years ago
Pharma
Coronavirus

Up­dat­ed: Ag­i­lent throws down $725M to dou­ble man­u­fac­tur­ing ca­pac­i­ty for nu­cle­ic acids to meet API de­mand

3 years ago
Financing
Manufacturing

Novotech's lat­est ac­qui­si­tions grow its US pres­ence and plant a Eu­ro­pean foothold

3 years ago
Deals
Outsourcing

Teva's opi­oid set­tle­ment moves for­ward with par­tic­i­pa­tion from 48 states

3 years ago
Pharma
Law

FDA ac­cepts one, de­lays an­oth­er; Da­ta, deals and dol­lars for slate of biotechs

3 years ago
News Briefing

Io­n­is sells par­tial stake in roy­al­ties from Spin­raza and No­var­tis car­dio drug to Roy­al­ty Phar­ma for $500M up­front

3 years ago
Deals

Voy­ager goes big, se­cur­ing mul­ti-bil­lion dol­lar gene ther­a­py de­vel­op­ment deal with Neu­ro­crine

3 years ago
Deals
Cell/Gene Tx

Emer­gent to cut over 130 po­si­tions to kick off new year

3 years ago
People
Manufacturing

Day One to file NDA for pe­di­atric brain can­cer drug by sum­mer

3 years ago
R&D

New year, new CEOs for Covid vac­cine mak­ers Cure­Vac and No­vavax

3 years ago
Coronavirus

Bio­Marin buffs up da­ta on he­mo­phil­ia A gene ther­a­py as FDA de­ci­sion dead­line ap­proach­es

3 years ago
R&D
Cell/Gene Tx

As­traZeneca bets up to $1.8B on Cin­Cor and its ex-Roche drug for hy­per­ten­sion

3 years ago
Deals
Pharma

Up­dat­ed: Ed­i­tas ed­its pipeline, lays off 20% and says bye to CSO to kick off #JPM23 

3 years ago
R&D

At #JPM23, an­oth­er rare dis­ease buy­out as Ipsen ac­quires Al­bireo for $952M

3 years ago
Deals
Pharma

Scoop: Rakuten bil­lion­aire lines up $70M for pho­toim­munother­a­py

3 years ago
Financing
Startups

Kro­nos and Genen­tech ink $20M can­cer dis­cov­ery pact

3 years ago
Deals
R&D

Up­dat­ed: New Ap­ple Tree biotech emerges with an­ti­bod­ies that might pair with Am­gen, Mi­rati's KRAS drugs

3 years ago
Financing
Startups

Ex­clu­sive: Eli Lil­ly boosts in­flam­ma­to­ry dis­ease pipeline, li­cens­es three can­di­dates from TRexBio

3 years ago
Deals
First page Previous page 393394395396397398399 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.